ACURA PHARMACEUTICALS, INC
Acura Pharmaceuticals filed an 8-K disclosing $141,607 in new loans from Abuse Deterrent Pharma, LLC, bringing the total secured promissory note principal to $11,435,886 with approximately $1,416,000 in accrued interest at 5.25%. The company warns that without additional financing by late-November 2026, it will be forced to scale back operations, furlough or lay off employees, terminate operations, or seek bankruptcy protection — which could result in a complete loss of shareholder value.
- Total secured promissory note principal now $11,435,886 with ~$1,416,000 accrued interest at 5.25% as of October 31, 2026.
- Company received $141,607 in new loans from AD Pharma on October 19 and October 30, 2026 for day-to-day operations.
- Default rate on overdue amounts is 7.5% per annum; events of default include failure to pay within 5 days of due date.
- Without additional financing by late-November 2026, company will furlough/lay off employees, terminate operations, or seek bankruptcy protection.
- The note maturity date and FDA NDA acceptance deadline for LTX-03 both fall on December 31, 2026, per forward-looking statement disclosures.
Price data unavailable.
A publicly traded company explicitly warning that failure to raise capital within ~4 weeks will force bankruptcy or operational shutdown is a rare, high-signal distress event.
Micro-cap pharma with OTC-traded stock (Expert Market) reliant on a single related-party lender (AD Pharma) for survival funding; LTX-03 NDA acceptance is the sole binary catalyst.
Company explicitly states inability to secure financing by late-November 2026 will force operational scale-back, furloughs, layoffs, or bankruptcy — potentially resulting in "complete loss of shareholder value." The $11.4M note and NDA deadline both mature December 31, 2026, creating a concentrated default risk window.